

## Monthly DRUP Study Newsletter #78, 01 October 2022

The Drug Rediscovery Protocol (DRUP Trial):

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile



PARIS 2022 ESMO congress




**Laurien Zeverijn and Birgit Geurts represented DRUP during the annual ESMO meeting in Paris 2022 with the abstracts**

*‘Limited effect of pembrolizumab in patients with breast cancer harbouring high mutational load 140-290 - results from the Drug Rediscovery Protocol (DRUP)’*

**and**

*‘Durvalumab in advanced, pre-treated microsatellite instability-high solid tumors: results of a tumor-agnostic DRUP trial cohort’.*



**Monthly highlight:**

**DRUP open for inclusion for more than 6 years**

## **Study update**

**DRUP has been open for inclusion for more than 6 years!** In September 2016 we included our first DRUP patient and now, six years later, more than 1200 patients have started one of the 32 treatments the study has to offer. With its 35 participating sites and 13 collaborating pharmaceutical companies (and more in an explorative phase) the study has become one of the biggest oncological interventional studies in The Netherlands. This is a great achievement, which we should all be very proud of. Without the support from all of you, this would not have been possible. Thank you and keep up the good work.

## **Scientific output**

The official analysis of the 3<sup>rd</sup> stage nivolumab cohort is ongoing and we are putting the finished touches to the manuscript. We hope to share the official results in the near future.

## **Information for participating sites**

Within DRUP, approximately 200 patients with a mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-h) tumor have been included. Immunotherapy has shown durable responses in this patient population, however, still a subset of patients do not respond. An important goal is to identify the subset of dMMR/MSI-h patients that may benefit from immunotherapy and this is still an ongoing challenge. Where single biomarkers, such as dMMR/MSI-h, have made a significant impact in selection of patients for treatment, the consensus is that a single biomarker may not be sufficient to improve treatment outcome. Therefore, multi-parameter analysis may be of added value, in which we will try to identify predictors of response based on pathology, radiology and whole genome sequencing data. However, to perform this analysis, we need your help! Therefore, we will ask the sites who have included dMMR/MSI-h patients to collect radiology data. We will contact the relevant sites in the very near future, and we would like to thank you in advance for your help!

## **Study team update**



Hi everyone! My name is Karlijn Verkerk and I am the newest addition to the DRUP study coordinating team. I will be working from the NKI-AvL. I am 25 years old and I graduated as a medical doctor this month at the Utrecht University. During one of my last clinical internships I worked on the oncology ward at Meander Medisch Centrum, where I learned about the DRUP trial. This sparked my interest, as I think that personalized medicine will become the future in oncology. I am therefore very excited to start my PhD in the DRUP team.

Furthermore, Henk Verheul, one of the co-principal investigators of DRUP is no longer working in the Radboud UMC, but is continuing his career in Erasmus MC from September 2022 onwards.

Warm regards,

Principal Investigators: Henk Verheul, Hans Gelderblom, Emile Voest

Study Coordinators: Laurien Zeverijn, Gijs de Wit, Birgit Geurts, Ilse Spiekman, Karlijn Verkerk

Clinical Project Manager: Lena Bilet

<b>Table 1: List of pharmaceutical companies &amp; study drugs</b>			
Confidential, list might be subjected to change			
<b>Currently available</b>			
<u>Amgen</u>	<u>Eisai</u>	<u>Bayer</u>	<u>Roche</u>
Panitumumab	Lenvatinib	Regorafenib	Erlotinib
			Trastuzumab+
<u>BMS</u>	<u>AstraZeneca</u>	<u>Clovis Oncology</u>	Pertuzumab
Nivolumab	Olaparib	Rucaparib	Vemurafenib+
Ipilimumab	Durvalumab		Cobimetinib
		<u>MSD</u>	Vismodegib
<u>Novartis</u>	<u>Pfizer</u>	Pembrolizumab	Atezolizumab+
Dabrafenib	Axitinib		bevacizumab
Nilotinib	Crizotinib	<u>Lilly</u>	Alectinib
Trametinib	Sunitinib	Abemaciclib	Entrectinib
Ribociclib	Palbociclib		
Alpelisib	Talazoparib,	<u>BI</u>	<u>Janssen</u>
	dacomitinib	Afatinib	Erdafitinib
	Lorlatinib		
<b>Committed</b>			
<u>Lilly</u>	<u>GSK</u>	<u>Merck</u>	
Selpercatinib	Niraparib	Tepotinib	

<b>Calendar &amp; publicity</b>
November 30 <sup>th</sup> IDMC meeting
December 20 <sup>th</sup> Pharma meeting

